⌕
NewAmsterdam Pharma · NAMS · Nasdaq
Tenet 58 · Mixed
Compare
$19.46−3.38%At closeTenet 58 · Mixed
$19.46−0.68 (−3.38%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

NewAmsterdam Pharma (NAMS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …

● Zacks Investment ResearchNov 4, 2026 · 09:56 ETEARNINGS EXPECTED BY FEB 23
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.5.…

● GlobeNewsWireNov 4, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib worldwide –…

● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November

NAARDEN, The Netherlands and MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …

● Defense WorldOct 16, 2026 · 03:41 ET
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $20.04 and last traded at $20.19, with a volume …

● GlobeNewsWireOct 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …

● GlobeNewsWireSep 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based…

● PRNewsWireSep 23, 2026 · 13:43 ET
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®

Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo (obicetrapib en monoterapia) y Evlarco (combinación a dosis…

● GlobeNewsWireSep 21, 2026 · 09:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-…

● Defense WorldSep 11, 2026 · 03:45 ETEARNINGS EXPECTED BY FEB 23
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis

NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of th…

● GlobeNewsWireSep 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral,…

● GlobeNewsWireSep 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.…

● GlobeNewsWireAug 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, …

● Defense WorldAug 16, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 23
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The in…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just NAMS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.